Pipeline

Cantabio's core research strategy focuses on the development of a pipeline of therapeutic candidates with novel mechanisms of action for preclinical testing and clinical development for Alzheimer’s, Parkinson’s diseases and diabetes, as well as other related indications. Cantabio’s pipeline represents a balanced R&D strategy aimed at generating a return on research and development investment, with a throughput of therapeutic candidates at different R&D stages ensuring a continuous supply of clinical candidates.

Cantabio is constantly searching for complementary technologies and R&D partnerships to complement the companies’ core scientific and technological intellectual property and capabilities. Cantabio has an on-going policy of review and acquisition of complementary intellectual property, whilst also pursing out-licensing opportunities of its selected therapeutic projects.